The expert hematologist from Plymouth University Medical Center discussed the long-term outcomes of patients receiving ibrutinib for mantle cell lymphoma at the ASH Annual Meeting and Exposition.
Simon Rule, MD, PhD
Advertisement
Articles by Simon Rule, MD, PhD
Advertisement
Latest Updated Articles
Simon Rule, MD, PhD, on Long-Term Outcomes with Ibrutinib Versus Prior Treatment RegimensPublished: January 2nd 2020 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
How Can Oncology Staffing Shortages Be Remedied?
2
Lifileucel Confers Durable Responses in Pretreated Advanced NSCLC Type
3
Glofitamab/Polatuzumab Vedotin Exhibits Response Durability in R/R LBCL
4
Atezolizumab Combo Elicits No Significant Benefit in Ovarian Cancer
5
